IDXG.US Interpace Biosciences, Inc. Common stock

Healthcare Health Care Providers & Services USA Stocks
6.05 USD
Close of Nov 15, 2026
0.0013 7.80
Market cap
USD 35.7M
P/E
1.3x
P/B
1.54x
ROE
7.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IDXG.US undervalued?

Graham number

The Graham number of Interpace Biosciences, Inc. Common stock cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Interpace Biosciences, Inc. Common stock fundamental analysis

No fundamental analysis for Interpace Biosciences, Inc. Common stock yet.

Interpace Biosciences, Inc. Common stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Interpace Biosciences, Inc. Common stock

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The …

Full company profile